BSH 2022 | Targeted therapy in CLL in 2022 and in the future
In this video, Barbara Eichhorst, MD, University Hospital Cologne, Cologne, Germany, gives an overview of her presentation at BSH 2022, which focused on targeted therapy in chronic lymphocytic leukemia (CLL) in 2022 and the future. Dr Eichhorst first discusses treatment options available to CLL patients, including continuous and time-limited approaches. Dr Eichhorst then highlights novel treatment regimens and clinical trials in CLL, including the FLAIR trial (ISRCTN01844152) investigating the use of ibrutinib in the frontline setting, and the benefit of combining venetoclax with obinutuzumab versus the use of fludarabine, cyclophosphamide and rituximab (FCR). This interview took place at the 62nd Annual Scientific Meeting of the British Society for Haematology (BSH) 2022, in Manchester, UK.
Disclosures
I receive honoraria for presentations and advisory board from several different pharmaceutical companies involved in targeted agents in CLL (Abbvie, BeiGene, BMS, Gilead, Janssen, MSD, Roche).
